BMRNBioMarin Pharmaceutical Inc.
Is it growing?
Neither accelerating nor breaking down: revenue growing +11% year on year, but earnings down −89% year on year and operating margin narrowing (−20.9 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +12% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 4.3% now against 25.1% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is BMRN growing?
BioMarin Pharmaceutical Inc. has grown revenue 15% a year over three years and 12% a year over five, with earnings per share compounding at −11%.
Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +12%
Revenue growth, 5-year rate · +15% over three · growth has picked up over the last three years
- Earnings per share, 3-year rate
- −11%
Earnings per share, 3-year rate · revenue +15% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 18
Years of annual history on file · FY2008 to FY2025, as filed
Details›
- Revenue FY2021
- $1.85B
- Revenue FY2022
- $2.10B
- Revenue FY2023
- $2.42B
- Revenue FY2024
- $2.85B
- Revenue FY2025
- $3.22B
Annual income statements as filed with the SEC.